Derry Sheena, Moore R Andrew, McQuay Henry J
Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
Cochrane Database Syst Rev. 2010 Nov 10(11):CD008040. doi: 10.1002/14651858.CD008040.pub2.
Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce nausea and vomiting commonly associated with migraine.
To determine the efficacy and tolerability of paracetamol (acetaminophen), alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine in adults.
We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies through 4 October 2010.
We included randomised, double-blind, placebo- or active-controlled studies using self-administered paracetamol to treat a migraine headache episode, with at least 10 participants per treatment arm.
Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and numbers needed to treat (NNT) or harm (NNH) compared to placebo or other active treatment.
Ten studies (2769 participants, 4062 attacks) compared paracetamol 1000 mg, alone or in combination with an antiemetic, with placebo or other active comparators, mainly sumatriptan 100 mg. For all efficacy outcomes paracetamol was superior to placebo, with NNTs of 12, 5.2 and 5.0 for 2-hour pain-free and 1- and 2-hour headache relief, respectively, when medication was taken for moderate to severe pain. Nausea, photophobia and phonophobia were reduced more with paracetamol than with placebo at 2 hours (NNTs of 7 to 11); more individuals were free of any functional disability at 2 hours with paracetamol (NNT 10); and fewer participants needed rescue medication over 6 hours (NNT 6).Paracetamol 1000 mg plus metoclopramide 10 mg was not significantly different from oral sumatriptan 100 mg for 2-hour headache relief; there were no 2-hour pain-free data. There was no significant difference between the paracetamol plus metoclopramide combination and sumatriptan for relief of "light/noise sensitivity" at 2 hours, but slightly more individuals needed rescue medication over 24 hours with the combination therapy (NNT 17).Adverse event rates were similar between paracetamol and placebo, and between paracetamol plus metoclopramide and sumatriptan. No serious adverse events occurred with paracetamol alone, but more "major" adverse events occurred with sumatriptan than with the combination therapy (NNH 32).
AUTHORS' CONCLUSIONS: Paracetamol 1000 mg alone is an effective treatment for acute migraine headaches, and the addition of 10 mg metoclopramide gives short-term efficacy equivalent to oral sumatriptan 100 mg. Adverse events with paracetamol did not differ from placebo; "major" adverse events were slightly more common with sumatriptan than with paracetamol plus metoclopramide.
偏头痛是一种常见的致残性疾病,给个人、医疗服务机构和社会带来负担。许多患者选择不寻求或无法寻求专业帮助,而是依赖非处方镇痛药。联合使用止吐药应有助于减轻偏头痛常见的恶心和呕吐症状。
确定对乙酰氨基酚(扑热息痛)单独使用或与止吐药联合使用,与安慰剂及其他有效干预措施相比,在治疗成人急性偏头痛方面的疗效和耐受性。
我们检索了Cochrane中心对照试验注册库、MEDLINE、EMBASE和牛津疼痛缓解数据库,纳入截至2010年10月4日的研究。
我们纳入了随机、双盲、安慰剂对照或活性药物对照研究,这些研究使用自行服用的对乙酰氨基酚治疗偏头痛发作,每个治疗组至少有10名参与者。
两位综述作者独立评估试验质量并提取数据。与安慰剂或其他活性治疗相比,达到各结局的参与者人数用于计算相对危险度以及治疗所需人数(NNT)或伤害所需人数(NNH)。
10项研究(2769名参与者,4062次发作)将1000毫克对乙酰氨基酚单独使用或与止吐药联合使用,与安慰剂或其他活性对照药物(主要是100毫克舒马曲坦)进行了比较。对于所有疗效结局,对乙酰氨基酚均优于安慰剂,在服用药物治疗中度至重度疼痛时,2小时无痛、1小时和2小时头痛缓解的NNT分别为12、5.2和5.0。2小时时,对乙酰氨基酚组恶心、畏光和畏声症状的减轻程度超过安慰剂组(NNT为7至11);2小时时,对乙酰氨基酚组更多个体无任何功能障碍(NNT为10);6小时内需要急救药物的参与者更少(NNT为6)。1000毫克对乙酰氨基酚加10毫克甲氧氯普胺在2小时头痛缓解方面与口服100毫克舒马曲坦无显著差异;无2小时无痛的数据。对乙酰氨基酚加甲氧氯普胺组合与舒马曲坦在2小时缓解“对光/噪声敏感”方面无显著差异,但联合治疗组在24小时内需要急救药物的个体略多(NNT为17)。对乙酰氨基酚与安慰剂之间、对乙酰氨基酚加甲氧氯普胺与舒马曲坦之间的不良事件发生率相似。单独使用对乙酰氨基酚未发生严重不良事件,但舒马曲坦组发生的“严重”不良事件多于联合治疗组(NNH为32)。
1000毫克对乙酰氨基酚单独使用是治疗急性偏头痛的有效方法,加用10毫克甲氧氯普胺可产生与口服100毫克舒马曲坦相当的短期疗效。对乙酰氨基酚的不良事件与安慰剂无差异;舒马曲坦组的“严重”不良事件比加用甲氧氯普胺的对乙酰氨基酚组略常见。